Clinicians using 18F-FDG PET on patients with cervical spinal cord compression may be able to predict an improved outcome after surgical decompression.
Imaging with 18F-FDG PET may predict outcomes for patients with degenerative cervical myelopathy, according to a study published in The Journal of Nuclear Medicine.
Researchers in Germany prospectively assessed regional changes in glucose metabolism in the cervical spinal cord using 18F-FDG PET in 20 patients with symptomatic degenerative monosegmental cervical stenosis who underwent decompressive surgery.
“To date, experiences with 18F-FDG PET in symptomatic patients with degenerative cervical spine stenosis and consecutive compressive myelopathy are very limited,” said one of the lead researchers, Norbert Galldicks, MD, in a release. "In the present study, we present the results of preoperative magnetic resonance imaging and 18F-FDG PET imaging and postoperative follow-up imaging 12 months after decompressive surgery. Imaging findings were correlated with the clinical outcome."
The researchers assessed patient functional status score, 18F-FDG uptake, and MR imaging changes pre- and postoperatively. The results showed that preoperatively, 10 patients had increased 18F-FDG uptake at the site of the spinal cord compression and were classified as myelopathy type 1.
The remaining patients had inconspicuous 18F-FDG uptake and were classified as myelopathy type 2. Postoperatively, those with myelopathy type 1 had a marked decrease in 18F-FDG uptake, but type 2 patients only demonstrated a moderate decline.
The researchers concluded that the focal glucose hypermetabolism at the level of cervical spinal cord compression may predict an improved outcome after surgical decompression.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.